Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline
Brain · 03.12.2024 · 147 (12) · 4094-4104
DOI: 10.1093/brain/awae211 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 28.06.2024. Verfasst von Débora E Peretti und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocentre and Faculty of Medicine, University of Geneva, G…. Hauptthemen laut MEDLINE: Alzheimer Disease, Glial Fibrillary Acidic Protein, Cognitive Dysfunction, Positron-Emission Tomography. Die Arbeit wurde bisher 66-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Private Foundation of Geneva University Hospitals, Association Suisse pour la Recherche sur la Maladie d'Alzheimer, Genève, Fondation Segré, Genève.
Themen: Demenz
Abstract (Originalsprache)
Increasing evidence shows that neuroinflammation is a possible modulator of tau spread effects on cognitive impairment in Alzheimer's disease. In this context, plasma levels of the glial fibrillary acidic protein (GFAP) have been suggested to have a robust association with Alzheimer's disease pathophysiology. This study aims to assess the correlation between plasma GFAP and Alzheimer's disease pathology, and their synergistic effect on cognitive performance and decline. A cohort of 122 memory clinic subjects with amyloid and tau PET, MRI scans, plasma GFAP and Mini-Mental State Examination (MMSE) was included in the study. A subsample of 94 subjects had a follow-up MMSE score at ≥1 year after baseline. Regional and voxel-based correlations between Alzheimer's disease biomarkers and plasma GFAP were assessed. Mediation analyses were performed to evaluate the effects of plasma GFAP on the association between amyloid and tau PET and between tau PET and cognitive impairment and decline. GFAP was associated with increased tau PET ligand uptake in the lateral temporal and inferior temporal lobes in a strong left-sided pattern independently of age, sex, education, amyloid and APOE status (β = 0.001, P < 0.01). The annual rate of MMSE change was significantly and independently correlated with both GFAP (β = 0.006, P < 0.01) and global tau standardized uptake value ratio (β = 4.33, P < 0.01), but not with amyloid burden. Partial mediation effects of GFAP were found on the association between amyloid and tau pathology (13.7%) and between tau pathology and cognitive decline (17.4%), but not on global cognition at baseline. Neuroinflammation measured by circulating GFAP is independently associated with tau Alzheimer's disease pathology and with cognitive decline, suggesting neuroinflammation as a potential target for future disease-modifying trials targeting tau pathology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocentre and Faculty of Medicine, University of Geneva, Geneva 1205, Switzerland.
- Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva 1205, Switzerland.
- Geneva Memory Centre, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva 1205, Switzerland.
- Division of Radiology, Geneva University Hospitals, Geneva 1205, Switzerland.
- Biological Psychiatry Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia 25125, Italy.
- Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger 4011, Norway.
ORCID-Profile: Débora E Peretti, Federica Ribaldi, Henrik Zetterberg, Valentina Garibotto
Förderung
- Private Foundation of Geneva University Hospitals
- Association Suisse pour la Recherche sur la Maladie d'Alzheimer, Genève
- Fondation Segré, Genève
- Race Against Dementia Foundation, London, UK
- Fondation Child Care, Genève
- Fondation Edmond J. Safra, Genève
- Fondation Minkoff, Genève
- Fondazione Agusta, Lugano
Zitieren
APA
Peretti, D. E., Boccalini, C., Ribaldi, F., Scheffler, M., Marizzoni, M., Ashton, N. J., Zetterberg, H., Blennow, K., Frisoni, G. B., & Garibotto, V. (2024). Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline. Brain, 147(12), 4094-4104. https://doi.org/10.1093/brain/awae211
Vancouver
Peretti DE, Boccalini C, Ribaldi F, Scheffler M, Marizzoni M, Ashton NJ, et al. Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline. Brain. 2024;147(12):4094-4104. doi:10.1093/brain/awae211
BibTeX
@article{Peretti2024,
author = {Peretti, Débora E and Boccalini, Cecilia and Ribaldi, Federica and Scheffler, Max and Marizzoni, Moira and Ashton, Nicholas J and Zetterberg, Henrik and Blennow, Kaj and Frisoni, Giovanni B and Garibotto, Valentina},
title = {Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline},
journal = {Brain},
year = {2024},
volume = {147},
number = {12},
pages = {4094--4104},
doi = {10.1093/brain/awae211}
}
EUVIMED